Recurrent Aortobronchial Fistula after Endovascular Stenting for Infected Pseudoaneurysm of the Proximal Descending Thoracic Aorta: Case Report

Sun-Geun Lee, M.D.1, Seung Hyong Lee, M.D.2, Won Kyoun Park, M.D.1, Dae Hyun Kim, M.D., Ph.D.1, Jae Won Song, M.D.1, Sang-Ho Cho, M.D., Ph.D.1

1Department of Thoracic and Cardiovascular Surgery, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine; 2Department of Thoracic and Cardiovascular Surgery, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea

ARTICLE INFO
Received October 12, 2020
Revised November 2, 2020
Accepted November 12, 2020

Corresponding author
Sang-Ho Cho
Tel 82-2-440-6158
Fax 82-2-440-8004
E-mail sinan75@khnmc.or.kr
ORCID https://orcid.org/0000-0001-5590-1904

Aortobronchial fistula (ABF) induced by an infected pseudoaneurysm of the thoracic aorta is a life-threatening condition. As surgical treatment is associated with significant mortality and morbidity, thoracic endovascular aneurysm repair (TEVAR) may be an alternative for the treatment of ABF. However, the long-term durability of this intervention is largely unknown and the recurrence of ABF is a potential complication. We experienced a case of recurrent ABF after stent grafting as an early procedure for an infected pseudoaneurysm of the thoracic aorta. Remnant ABF, bronchial and/or aortic wall erosion, vasa vasorum connected with ABF, and recurrent local inflammation of the thin aortic wall around ABF might cause recurrent hemoptysis. As a result, we suggest that TEVAR should be considered as a bridge therapy for the initial treatment of ABF resulting from an infected pseudoaneurysm, and that several options, such as second-stage surgery, should be considered to prevent the recurrence of ABF.

Keywords: Aorta, Aneurysm, Infected, Bronchial fistula, Endovascular procedures, Case report

Case report

A 59-year-old man was admitted to the emergency room following the occurrence of massive hemoptysis with a high-grade fever. The patient’s blood pressure was 110/70 mm Hg and his pulse rate was 100 beats per minute. The patient’s clinical data on admission were as follows: white blood cell count, 5,400/mm³; hemoglobin, 10.8 g/dL; platelet count, 298×10³/mm³; and C-reactive protein, 11.2 mg/dL. One month ago, he had presented to an outpatient clinic to investigate the origin of the fever and oral antibiotics had been administered under the diagnosis of a urinary tract infection (urine culture: Salmonella species). Enhanced computed tomography (CT) of the chest revealed a saccular aortic aneurysm of the proximal descending thoracic aorta (Fig. 1). The urine and sputum culture reported Salmonella species. Initially, under a diagnosis of aortobronchial fistula (ABF) from the infected pseudoaneurysm, we planned to perform open surgery to remove the ABF. However, due to recurrent hemoptysis, emergency stent grafting was performed in order to control the hemoptysis (36×120 mm, S&G SEAL; S&G Biotech Inc., Seoul, Korea). Intravenous antibiotics were given daily for 1 month, according to the guidelines for the management of infective endocarditis, and the patient was then switched to oral antibiotics. The duration of oral antibiotic therapy (levofloxacin) was 60 days and the patient recovered uneventfully. Chest CT on postoperative day 50 confirmed shrinkage of the aneurysm with disappearance of the pulmonary infiltrates surrounding the aneurysmal wall, and there was no endoleak. Approximately 4 months after stent grafting, the patient was readmitted with recurrent mild hemoptysis. The patient’s blood pressure was 120/70 mm Hg and his pulse rate was 90 beats per minute. His clinical data on admission were as follows: white blood cell count, 10,600/mm³; hemoglobin, 11.5 g/dL; hematocrit,
32.8%; platelet count, 27.0×10⁴/mm³; and C-reactive protein, 3.5 mg/dL. Chest CT showed pulmonary infiltrates adjacent to the regressed aortic aneurysm wall (Fig. 2A). Bronchoscopy revealed scattered blood clots extending from the left upper lobe to the left main bronchus with no evidence of an active focus of hemoptysis. We performed eradication of all previous infected tissue, including the stent graft, and reconstruction of the distal ascending aorta, aortic arch, and proximal descending thoracic aorta with a woven Dacron graft under cardiopulmonary bypass. Pathological examination of the incised aorta revealed atherosclerosis with acute and chronic inflammation. However, cultures of the aortic wall and the graft did not detect any bacteria. It would seem that remnant ABF (Fig. 2B, black arrow), vasa vasorum connected with the ABF, and recurrent local inflammation of the thin aortic wall around the ABF (Fig. 2B, white arrow) might have caused recurrent hemoptysis. After intravenous antibiotics were given daily for 1 month, he was discharged home without any complications and was followed up without the recurrence of ABF at an outpatient clinic for 80 months.

The patient provided informed consent for the publication of his clinical details and images.
Discussion

ABF is a rare, life-threatening condition that represents a communication between the thoracic aorta and the tracheobronchial airway. An ABF is characterized by massive or recurrent hemoptysis in patients with a history of previously treated thoracic aortic pathology, atherosclerotic aneurysms, traumatic injuries of the descending thoracic aorta, and infected aortic pseudoaneurysm [1,2]. The traditional treatment of ABF involves thoracotomy and in situ graft replacement or extra-anatomical bypass. Early mortality rates after surgical repair were reported to be 18% to 24%, with substantial postoperative morbidity [3]. Although early open thoracic surgery under cardiopulmonary bypass is essential, the high mortality and morbidity associated with surgery may lead surgeons to consider other options; in particular, thoracic endovascular aneurysm repair (TEVAR) may be an alternative for the treatment of ABF. This treatment is less invasive and associated with acceptable early mortality and morbidity rates [1,2,4-6]. In 2013, Canaud et al. [4] carried out a systematic review of the outcomes of TEVAR for ABF, reporting 134 cases with excellent short-term results in comparison with the results of open surgery, including a low 30-day mortality rate (5.9%) and no cases of paraplegia. The incidence of severe complications (pulmonary complications, sepsis, myocardial ischemia) was only 10.4%. In a review of the literature, Riesenman et al. [1] reported a 30-day mortality rate of 1.5% in 67 patients undergoing TEVAR for ABF.

However, the long-term durability of stent grafts remains unknown. Concerns about the risk of the recurrence of ABF or infection of the stent graft have been raised [7-9]. Canaud et al. [4] reported that recurrence of ABF and stent graft infections after TEVAR were observed in 11.2% and 1.7% of patients, respectively. Surgical conversion was required in 4.3% of the patients [4-7]. In cases of ABF resulting from an infected pseudoaneurysm, an infectious break in the wall of an artery with the formation of a saccular outpouching and concomitant systemic infection may aggravate the outcomes after TEVAR [9,10]. In conclusion, in the current case report of a recurrent ABF at the proximal descending thoracic aorta, we suggest that TEVAR should be considered as bridge therapy for the initial treatment of ABF resulting from an infected pseudoaneurysm and that several options, such as second-stage surgery, should be considered to prevent the recurrence of ABF.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

ORCID

Sun-Geun Lee: https://orcid.org/0000-0002-7509-0229
Seung Hyong Lee: https://orcid.org/0000-0002-9839-6431
Won Kyoun Park: https://orcid.org/0000-0002-1693-0582
Dae Hyun Kim: https://orcid.org/0000-0002-8434-7380
Jae Won Song: https://orcid.org/0000-0002-3530-0623
Sang-Ho Cho: https://orcid.org/0000-0001-5590-1904

References

1. Riesenman PJ, Brooks JD, Farber MA. Thoracic endovascular aortic repair of aortobronchial fistulas. J Vasc Surg 2009;50:992-8.
2. Kawaharada N, Kurimoto Y, Ito T, et al. Endovascular stent-graft repair of aortobronchial fistulas. Ann Thorac Surg 2012;94:524-9.
3. Nishizawa J, Matsumoto M, Sugita T, et al. Surgical treatment of five patients with aortobronchial fistula in the aortic arch. Ann Thorac Surg 2004;77:1821-3.
4. Canaud L, Ozdemir BA, Bahia S, Hinchliffe R, Loftus I, Thompson M. Thoracic endovascular aortic repair for aortobronchial fistula. Ann Thorac Surg 2013;96:1117-21.
5. Bailey CJ, Force S, Milner R, Kasirajan K, Veeraswamy RK. Thoracic endovascular repair as a safe management strategy for aortobronchial fistulas. J Vasc Surg 2011;53:1202-9.
6. Bozzani A, Arici V, Odero A. Aortic stentgraft in aortobronchial fistula is a bridge solution? Ann Thorac Surg 2013;95:381-2.
7. Canaud L, D’Annoville T, Ozdemir BA, Marty–Ane C, Alric P. Combined endovascular and surgical approach for aortobronchial fistula. J Thorac Cardiovasc Surg 2014;148:2108-11.
8. Nguyen T, Peters P, McGahan T, Shah P. Staged management of a primary aortobronchial fistula: a novel approach using a trapezius flap repair. Heart Lung Circ 2012;21:292-4.
9. Touma Y, Demondion P, Rama A, Leprince P. Aortobronchial fistula in the presence of a midgraft hole after endovascular repair of thoracic aortic aneurysms. Eur J Cardiothorac Surg 2013;43:1259-61.
10. De Rango P, Estrera AL, Azizzadeh A, Keyhani K, Safi HJ. Two-stage safe repair of aortobronchial fistula. Ann Thorac Surg 2010;89:275-7.